Bibliographic information
GuidelineTherapeutics and COVID-19: living guideline, 10 November 2023.
Year of Publication2023
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
Originally developed
We recommend against treatment with molnupiravir for patients with non-severe COVID-19 at low risk of hospitalization
Recommended against
Strong
Notes and Remarks
Remarks
- See Section 6 regarding identifying patients at low risk.
- The marginal benefits of molnupiravir for patients at low risk of hospitalization (those expected to have a 0.5% risk of hospital admission) suggest most patients would not want to use this treatment.
- Given considerations regarding resources and equity, the GDG concluded that health care systems may reasonably not offer this drug to patients at low risk of hospitalization.
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
Therapeutics and COVID-19: living guideline, August 2025
Year2025
InstitutionWorld Health Organization